NEWTON, Mass.

牛顿，马萨诸塞州

,

，

March 24, 2026

2026年3月24日

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:

/PRNewswire/ -- Karyopharm Therapeutics Inc. (纳斯达克:

KPTI

KPTI

), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exercised in full..

），一家处于商业化阶段的制药公司，致力于开创性癌症疗法，今日宣布已与RA资本管理公司达成证券购买协议，进行一项预计在扣除配售代理费和发行费用前将带来约3000万美元总收益的私募配售，并且如果随附的认股权证全额行使，还将额外获得约4400万美元的总收益。

In the private placement, the Company agreed to sell 1,030,354 shares of common stock at a price of $6.785 per share, 3,391,164 pre-funded warrants at a price of $6.7849 per pre-funded warrant, and accompanying warrants to purchase 4,421,518 shares of common stock with an exercise price of $10.00 per share.

在私募配售中，公司同意以每股6.785美元的价格出售1,030,354股普通股，以每份6.7849美元的价格出售3,391,164份预融资权证，并附带可购买4,421,518股普通股的权证，行权价格为每股10.00美元。

The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable and will not expire. The accompanying warrants will be immediately exercisable and will expire 30 days following the public announcement by the Company of topline results from the Phase 3 XPORT-EC-042 clinical trial of selinexor in patients with endometrial cancer..

预融资权证的行使价格为每股普通股 0.0001 美元，可立即行使且无到期日。附带的权证将可立即行使，并在公司公布 selinexor 针对子宫内膜癌患者的三期 XPORT-EC-042 临床试验的初步结果后的 30 天到期。

The private placement is expected to close on or about March 26, 2026, subject to the satisfaction of customary closing conditions. The private placement was priced at-the-market under Nasdaq rules.  The Company expects that the net proceeds of the private placement, together with its existing liquidity, including cash, cash equivalents and investments, as well as cash flow from net product revenue and license and other revenue, will enable it to fund its current operating plans into late Q3 2026..

预计私募将于 2026 年 3 月 26 日或前后完成，但需满足惯例的交割条件。此次私募根据纳斯达克规则以市价定价。公司预计，私募的净收益加上现有的流动性（包括现金、现金等价物和投资），以及来自产品净收入和许可及其他收入的现金流，将使其能够为当前的运营计划提供资金至 2026 年第三季度末。

The Company intends to use the proceeds from the private placement for general corporate purposes, including to support the Company's ongoing and planned clinical trial activities.

公司打算将私募所得款项用于一般公司用途，包括支持公司正在进行和计划中的临床试验活动。

Jefferies and Piper Sandler acted as placement agents for the private placement.

Jefferies和Piper Sandler在此次私募中担任配售代理。

The offer and sale of the shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) are not being registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state securities laws.

本次普通股股份、预融资认股权证、认股权证或任何其他证券（包括行使预融资认股权证和认股权证可获得的普通股股份）的发行和销售未根据修订后的《1933年证券法》（“证券法”）或任何州证券法进行注册。

The shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and any applicable state securities laws..

普通股、预融资认股权证、认股权证或任何其他证券（包括行使预融资认股权证和认股权证可发行的普通股）不得在美国境内发售或出售，除非根据《证券法》及任何适用的州证券法的注册要求豁免进行。

This press release does not constitute an offer to sell or the solicitation of an offer to buy shares of common stock, pre-funded warrants, warrants, or any other securities, nor shall there be any offer, solicitation or sale of shares of common stock, pre-funded warrants, warrants, or any other securities (including the shares of common stock issuable upon exercise of the pre-funded warrants and warrants) in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful..

本新闻稿不构成出售或招揽购买普通股、预融资认股权证、认股权证或任何其他证券的要约，也不应在任何州或其他司法管辖区进行普通股、预融资认股权证、认股权证或任何其他证券（包括行使预融资认股权证和认股权证可发行的普通股）的要约、招揽或销售，若此类要约、招揽或销售在该州或司法管辖区属违法行为。

About Karyopharm Therapeutics

关于Karyopharm治疗学

Karyopharm Therapeutics Inc. (Nasdaq:

Karyopharm Therapeutics Inc.（纳斯达克：

KPTI

KPTI

) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis.

）是一家处于商业化阶段的制药公司，致力于开创癌症治疗新方法，其动力来源于对癌症患者非凡力量和勇气的信念。自成立以来，Karyopharm一直是解决核输出失调（肿瘤发生的一个基本机制）口服化合物领域的行业领导者。

Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO®) and China.

Karyopharm的先导化合物、也是首款口服输出蛋白1（XPO1）抑制剂XPOVIO®（selinexor），已在美国获批，并由该公司在三种肿瘤适应症中上市销售。该药物还在50个非美国地区和国家的不同适应症中获得了监管批准，包括欧盟、英国（作为NEXPOVIO®）和中国。

Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL)..

Karyopharm 的研发管线专注于多种高需求未满足的癌症适应症，包括多发性骨髓瘤、子宫内膜癌、骨髓纤维化和弥漫性大B细胞淋巴瘤 (DLBCL)。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the expected closing date of the private placement, the Company's expected cash runway following closing of the private placement, and the Company's expected use of proceeds from the private placement.

本新闻稿包含《1995年私人证券诉讼改革法案》意义上的前瞻性陈述。这些前瞻性陈述包括有关私募预计完成日期、公司预计在私募完成后的现金跑道，以及公司预计对私募所得款项的用途等内容。

Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO or that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue.

此类声明受到诸多重要因素、风险和不确定性的制约，其中许多因素超出了Karyopharm的控制范围，可能导致实际事件或结果与Karyopharm当前的预期存在重大差异。例如，无法保证Karyopharm将成功商业化XPOVIO，也无法保证Karyopharm的任何药物候选物（包括selinexor）能够成功完成必要的临床开发阶段，亦无法保证Karyopharm的任何药物候选物的开发将继续进行。

Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; the ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; Karyopharm's results of clinical trials and preclinical trials, including subsequent analysis of existing data and new data received from ongoing and future trials.

此外，无法保证Karyopharm的候选药物组合在开发或商业化方面的任何积极进展会导致股价上涨。管理层的预期以及因此本新闻稿中的任何前瞻性陈述也可能受到与许多其他因素相关的风险和不确定性的影响，包括以下几点：XPOVIO在商业市场中的接受程度、商业化XPOVIO或Karyopharm任何获得监管批准的候选药物所需的时间和成本；获得并保持XPOVIO或Karyopharm任何获得监管批准的候选药物的监管批准的能力；Karyopharm的临床试验和临床前试验结果，包括对现有数据的后续分析以及从正在进行和未来的试验中收到的新数据。

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.

XPOVIO® 和 NEXPOVIO® 是 Karyopharm Therapeutics Inc. 的注册商标。

SOURCE Karyopharm Therapeutics Inc.

来源：Karyopharm Therapeutics Inc.

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示